Identification of 3-(acylamino)azepan-2-ones as stable broad-spectrum chemokine inhibitors resistant to metabolism in vivo

Journal of Medicinal Chemistry

Volumn 48, Issue 3, 2005, Pages 867-874

  Fox, David J ^a   Reckless, Jill ^b   Wilbert, Sibylle M ^c,d   Greig, Ian ^a   Warren, Stuart ^a   Grainger, David J ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Poniard Pharmaceuticals Inc   (United States)

^d ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (10' UNDECANOYLAMINO)PYRROLIDIN 2 ONE; 3 (ACYLAMINO)AZEPAN 2 ONE DERIVATIVE; 3 (HEXADEC 9' ENOYL)AMINOAZEPAN 2 ONE; 3 (OCTADEC 9' ENOYL)AMINOAZEPAN 2 ONE; 3 (UNDEC 10' ENOYL)AMINOAZEPAN 2 ONE; 3 (UNDEC 10' YNOYL)AMINOAZEPAN 2 ONE; 3 DODECANOYLAMINOAZEPAN 2 ONE; 3 HEXADECANOYLAMINOAZEPAN 2 ONE; 3 OCTADECANOYLAMINOAZEPAN 2 ONE; 3 TETRADECANOYLAMINOAZEPAN 2 ONE; 3 UNDECANOYLAMINOAZEPAN 2 ONE; ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR ANTAGONIST; GLUTARIMIDE DERIVATIVE; LACTAM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; RING OPENING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; AZEPINES; BIOLOGICAL AVAILABILITY; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; INJECTIONS, SUBCUTANEOUS; LACTAMS; MICE; PIPERIDONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 13444292881     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049365a     Document Type: Article

References (23)

1. Bebo, B. F., Jr.; Yong, T.; Orr, E. L.; Linthicum, D. S. Hypothesis: A possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. J. Neurosci. Res. 1896, 45, 340-348.
2. Franceschi, C.; Bonafe, M.; Valensin, S.; Olivieri, F.; De Luca, M.; Ottavianni, E.; De Benedictis, G. Inflamm-aging - An evolutionary perspective on immunosenescence. Ann. NY Acad. Sci. 2000, 908, 244-254.
3. Mennicken, F.; Maki, R.; de Souza, E. B.; Quirion, R. Chemokines and chemokine receptors in the CNS: A possible role in neuroinflammation and patterning. Trends Pharmacol. Sci. 1999, 20, 73-78.
4. Rogers J.; Shen, Y. A perspective on inflammation in Alzheimer's disease. Ann. NY Acad. Sci. 2000, 924, 132-135.
5. Sullivan, G. W.; Sarembock, I. J.; Linden, J. The role of inflammation in vascular diseases. J. Leukocyte Biol. 2000, 67, 591-602.
6. Watanabe T.; Fan, J. L. Atherosclerosis and inflammation - Mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Int. J. Cardiol. 1998, 66 (Suppl 1), S45-S53.
7. Gerard, C.; Rollins, B. J. Chemokines and disease. Nat. Immunol. 2001, 2, 108-115.
8. Horuk, R. Chemokine receptors. Cytokine Growth Factor Rev. 2001, 12, 313-335
9. Rollins, B. J.; Chemokines. Blood 1997, 90, 909-928.
10. Luster, A. D. Chemokines - Chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998, 338, 436-445.
11. Thelen, M. Dancing to the tune of chemokines. Nat. Immunol. 2001, 2, 129-134.
12. Reckless, J.; Grainger, D. J. Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines. Biochem. J. 1999, 340, 803-811.
13. Reckless, J.; Tatalick, L. M.; Grainger, D. J. The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo. Immunology 2001, 103, 244-254.
14. Grainger D. J.; Reckless, J. Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo. Biochem. Pharmacol. 2003, 65, 1027-1034.
15. Naidu, B. V.; Farivar, A. S.; Krishnadasan, B.; Woolley, S. M.; Grainger, D. J.; Verrier, E. D.; Mulligan, M. S. Broad-spectrum chemokine inhibition ameliorates experimental obliterative bronchiolitis. Ann. Thorac. Surg. 2003, 75, 1118-1122.
16. Wilbert, S. M.; Engrissei, G.; Yau, E. K; Grainger, D. J.; Tatalick, L.; Axworthy, D. B. Quantitative analysis of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal standard. Anal. Biochem. 2000, 278, 14-21.
17. Fox, D. J.; Reckless, J.; Warren, S. G.; Grainger, D. J. Design, synthesis, and preliminary pharmacological evaluation of N-acyl-3- aminoglutarimides as broad-spectrum chemokine inhibitors in vitro and anti-inflammatory agents in vivo. J. Med. Chem. 2002, 45, 360-370.
18. Reist, M.; Carrupt, P. A.; Francotte, E.; Testa, B. Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem. Res. Toxicol. 1998, 11, 1521-1528.
19. Eriksson, T.; Bjorkman, S.; Roth, B.; Fyge, A.; Hoglund, P. Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 1998, 10, 223-228.
20. Pellegata, R.; Pinza, M.; Pifferi, G. An improved synthesis of gamma-, delta-, and epsilon-lactams. Synthesis 1978, 614-616.
21. Rezler, E. M.; Fenton, R. R.; Esdale, W. J.; McKeage, M. J.; Russell, P. J.; Hambley, T. W. Preparation, characterization, DNA binding, and in vitro cytotoxicity of the enantiomers of the platinum(II) complexes N-methyl-, N-ethyl- and N, N-dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum (II). J. Med. Chem. 1997, 40, 3508-3515.
22. Boyle, W. J.; Sifniades, S.; Van Peppen, J. V. Asymmetric transformation of α-amino-ε-caprolactam, a lysine precursor. J. Org. Chem. 1979, 44, 4841-4847.
23. Frow, E. K.; Reckless J.; Grainger, D. J. Tools for anti-inflammatory drug design: In vitro models of leukocyte migration. Med. Res. Rev. 2004, 24, 276-298.